Research Oversight Committees

Five committees have unique roles to guide, review and evaluate, and implement clinical trials in accordance with the group’s strategic themes, strengths, and the research needs of the overall National Clinical Trials Network.   

The Research Strategy Committee (RSC) focuses on study development and will provide feedback and recommendations to the disease site and scientific core committees. This committee also will provide regular reports to the NRG Oncology Foundation Board.

The Protocol Operations Management (POM) Committee is responsible for monitoring the progress of activated protocols. The POM Committee receives reports from the cancer disease site committees and the scientific non-disease site committees, assesses trial accrual and other performance metrics and recommends actions for accrual enhancement as needed.

Governed by the NCI Data Monitoring Policy, the Data Monitoring Committee (DMC) reviews the efficacy and morbidity data for Phase II randomized and Phase III NRG Oncology clinical trials to ensure that decisions regarding continuation of these trials are scientifically sound and ethically responsible. The DMC makes recommendations to the group chairs for a final decision. The DMC is chaired by a non-NRG Oncology member. The Early Phase Trial Oversight Committee (EPTOC)  provides oversight for the group’s Phase I and non-randomized Phase II trials and for the safety lead-in components of protocols.

The Group Executive Committee is composed of the NRG Oncology group chairs, deputy group chairs, group statisticians, and executive directors of the operations center, and will be chaired by the presiding group chair. It meets regularly to ensure that the priorities set by the NRG Oncology Foundation Board are operationalized in the group’s research strategy and supported by appropriate operations center resources.